Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vitiligo | 51 | 2022 | 92 | 24.610 |
Why?
|
Skin | 20 | 2022 | 303 | 6.720 |
Why?
|
Melanocytes | 15 | 2022 | 65 | 5.610 |
Why?
|
Hypopigmentation | 7 | 2022 | 10 | 4.250 |
Why?
|
Skin Pigmentation | 7 | 2021 | 31 | 3.040 |
Why?
|
Alopecia Areata | 6 | 2018 | 9 | 3.010 |
Why?
|
Autoimmunity | 10 | 2021 | 208 | 2.930 |
Why?
|
CD8-Positive T-Lymphocytes | 11 | 2021 | 631 | 2.810 |
Why?
|
Immunotherapy | 4 | 2020 | 202 | 2.510 |
Why?
|
Autoimmune Diseases | 6 | 2021 | 192 | 2.180 |
Why?
|
Chemokine CXCL10 | 10 | 2022 | 49 | 1.920 |
Why?
|
Interferon-gamma | 10 | 2022 | 537 | 1.890 |
Why?
|
T-Lymphocytes | 5 | 2020 | 903 | 1.850 |
Why?
|
Janus Kinase Inhibitors | 3 | 2020 | 10 | 1.840 |
Why?
|
T-Lymphocytes, Regulatory | 4 | 2022 | 163 | 1.800 |
Why?
|
Immunologic Memory | 6 | 2021 | 322 | 1.750 |
Why?
|
Melanoma, Experimental | 2 | 2021 | 43 | 1.680 |
Why?
|
Pyrazoles | 5 | 2022 | 60 | 1.670 |
Why?
|
Skin Diseases | 4 | 2022 | 69 | 1.650 |
Why?
|
Receptors, CXCR3 | 4 | 2020 | 28 | 1.630 |
Why?
|
Chemokines | 3 | 2021 | 90 | 1.540 |
Why?
|
Disease Models, Animal | 11 | 2022 | 1799 | 1.380 |
Why?
|
Humans | 63 | 2022 | 48594 | 1.340 |
Why?
|
Animals | 33 | 2022 | 17856 | 1.300 |
Why?
|
Simvastatin | 2 | 2017 | 21 | 1.200 |
Why?
|
Chemokine CXCL9 | 5 | 2020 | 20 | 1.200 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 694 | 1.160 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2017 | 165 | 1.150 |
Why?
|
Signal Transduction | 8 | 2020 | 2730 | 1.090 |
Why?
|
Lupus Erythematosus, Cutaneous | 2 | 2021 | 13 | 1.040 |
Why?
|
Dermatology | 3 | 2019 | 45 | 1.030 |
Why?
|
Mice | 21 | 2022 | 9050 | 1.000 |
Why?
|
Immunity, Innate | 8 | 2021 | 688 | 0.940 |
Why?
|
RNA, Small Cytoplasmic | 1 | 2021 | 5 | 0.900 |
Why?
|
Lupus Erythematosus, Discoid | 1 | 2021 | 7 | 0.880 |
Why?
|
Receptors, CCR5 | 1 | 2021 | 51 | 0.870 |
Why?
|
Biological Products | 1 | 2022 | 63 | 0.860 |
Why?
|
Cancer Vaccines | 1 | 2021 | 46 | 0.860 |
Why?
|
Lupus Nephritis | 1 | 2021 | 28 | 0.860 |
Why?
|
Cross-Priming | 1 | 2020 | 17 | 0.830 |
Why?
|
Hair Dyes | 2 | 2017 | 5 | 0.810 |
Why?
|
Epidermis | 2 | 2018 | 35 | 0.810 |
Why?
|
Pyrimidines | 6 | 2021 | 104 | 0.800 |
Why?
|
Immunity, Cellular | 4 | 2019 | 179 | 0.790 |
Why?
|
Interferon Type I | 2 | 2020 | 157 | 0.790 |
Why?
|
Mice, Inbred C57BL | 10 | 2021 | 2901 | 0.760 |
Why?
|
Efficiency | 1 | 2019 | 41 | 0.740 |
Why?
|
DNA-Binding Proteins | 3 | 2021 | 1130 | 0.730 |
Why?
|
Interleukin-15 | 1 | 2018 | 15 | 0.720 |
Why?
|
Antibodies, Blocking | 1 | 2018 | 39 | 0.720 |
Why?
|
Immunosuppressive Agents | 2 | 2017 | 230 | 0.700 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 139 | 0.700 |
Why?
|
Melanoma | 1 | 2021 | 283 | 0.700 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 182 | 0.680 |
Why?
|
Skin Lightening Preparations | 1 | 2017 | 3 | 0.660 |
Why?
|
Blister | 1 | 2017 | 11 | 0.660 |
Why?
|
T-Lymphocyte Subsets | 1 | 2019 | 256 | 0.660 |
Why?
|
Lymphocyte Count | 1 | 2017 | 73 | 0.650 |
Why?
|
Stress, Physiological | 2 | 2016 | 177 | 0.630 |
Why?
|
Bullying | 1 | 2016 | 9 | 0.620 |
Why?
|
Phenols | 1 | 2017 | 61 | 0.620 |
Why?
|
Nitriles | 4 | 2021 | 52 | 0.610 |
Why?
|
Antibodies | 1 | 2017 | 161 | 0.610 |
Why?
|
Patient Satisfaction | 1 | 2019 | 357 | 0.600 |
Why?
|
Mice, Transgenic | 5 | 2021 | 1125 | 0.590 |
Why?
|
Melanins | 1 | 2015 | 16 | 0.590 |
Why?
|
Wnt Signaling Pathway | 1 | 2015 | 57 | 0.580 |
Why?
|
Organ Specificity | 1 | 2016 | 175 | 0.580 |
Why?
|
Delivery of Health Care | 1 | 2019 | 309 | 0.570 |
Why?
|
Ultraviolet Therapy | 3 | 2022 | 8 | 0.570 |
Why?
|
Genetic Vectors | 1 | 2020 | 680 | 0.570 |
Why?
|
Hair | 1 | 2015 | 72 | 0.570 |
Why?
|
Male | 18 | 2021 | 23091 | 0.560 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2021 | 573 | 0.540 |
Why?
|
Psoriasis | 2 | 2016 | 46 | 0.540 |
Why?
|
Adult | 11 | 2021 | 13144 | 0.490 |
Why?
|
Severity of Illness Index | 6 | 2020 | 1154 | 0.470 |
Why?
|
Kidney Tubular Necrosis, Acute | 1 | 2021 | 2 | 0.460 |
Why?
|
Ureteral Obstruction | 1 | 2021 | 9 | 0.450 |
Why?
|
Genome-Wide Association Study | 3 | 2021 | 285 | 0.440 |
Why?
|
Adaptive Immunity | 3 | 2017 | 84 | 0.420 |
Why?
|
Kidney Transplantation | 1 | 2021 | 178 | 0.410 |
Why?
|
Dermatitis, Contact | 1 | 2010 | 11 | 0.410 |
Why?
|
Keratinocytes | 2 | 2022 | 49 | 0.390 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2021 | 151 | 0.390 |
Why?
|
Receptors, CCR6 | 2 | 2022 | 10 | 0.390 |
Why?
|
Thrombosis | 1 | 2021 | 188 | 0.380 |
Why?
|
B-Lymphocytes | 2 | 2018 | 546 | 0.380 |
Why?
|
Female | 15 | 2021 | 26148 | 0.380 |
Why?
|
Double-Blind Method | 3 | 2021 | 545 | 0.380 |
Why?
|
Young Adult | 4 | 2021 | 3621 | 0.380 |
Why?
|
Apoptosis | 1 | 2015 | 1026 | 0.380 |
Why?
|
Exophiala | 1 | 2008 | 1 | 0.380 |
Why?
|
Leg Dermatoses | 1 | 2008 | 3 | 0.370 |
Why?
|
Biomarkers | 3 | 2020 | 962 | 0.370 |
Why?
|
Clonal Anergy | 2 | 2009 | 26 | 0.370 |
Why?
|
Dermatomycoses | 1 | 2008 | 11 | 0.370 |
Why?
|
Middle Aged | 8 | 2021 | 13423 | 0.370 |
Why?
|
Adolescent | 4 | 2021 | 5306 | 0.350 |
Why?
|
Oxidative Stress | 2 | 2021 | 245 | 0.330 |
Why?
|
gp100 Melanoma Antigen | 2 | 2020 | 3 | 0.330 |
Why?
|
Phenotype | 3 | 2021 | 1007 | 0.320 |
Why?
|
Case-Control Studies | 2 | 2020 | 885 | 0.300 |
Why?
|
STAT1 Transcription Factor | 2 | 2016 | 31 | 0.300 |
Why?
|
Consensus | 3 | 2021 | 114 | 0.290 |
Why?
|
Administration, Oral | 2 | 2017 | 292 | 0.290 |
Why?
|
Lymphocyte Activation | 3 | 2018 | 730 | 0.280 |
Why?
|
Interleukin-17 | 2 | 2017 | 71 | 0.280 |
Why?
|
Treatment Outcome | 5 | 2022 | 3803 | 0.270 |
Why?
|
Inflammation | 3 | 2016 | 941 | 0.260 |
Why?
|
Skin Physiological Phenomena | 2 | 2014 | 14 | 0.260 |
Why?
|
Cytokines | 2 | 2020 | 820 | 0.250 |
Why?
|
Programmed Cell Death 1 Receptor | 2 | 2020 | 55 | 0.230 |
Why?
|
Tissue Distribution | 1 | 2022 | 237 | 0.230 |
Why?
|
Cell Differentiation | 3 | 2016 | 1232 | 0.220 |
Why?
|
Phototherapy | 2 | 2022 | 21 | 0.220 |
Why?
|
Gene Ontology | 1 | 2021 | 32 | 0.220 |
Why?
|
Republic of Korea | 1 | 2021 | 21 | 0.220 |
Why?
|
CD28 Antigens | 2 | 2015 | 39 | 0.220 |
Why?
|
Autoantigens | 3 | 2021 | 124 | 0.220 |
Why?
|
Piperidines | 2 | 2020 | 36 | 0.220 |
Why?
|
Dermatologic Agents | 1 | 2021 | 16 | 0.220 |
Why?
|
Epidemiologic Studies | 1 | 2021 | 40 | 0.210 |
Why?
|
Ointments | 1 | 2020 | 5 | 0.210 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 69 | 0.210 |
Why?
|
Hyaluronan Receptors | 1 | 2020 | 34 | 0.210 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 107 | 0.210 |
Why?
|
Skin Cream | 1 | 2020 | 1 | 0.210 |
Why?
|
Mice, Mutant Strains | 1 | 2021 | 307 | 0.210 |
Why?
|
Receptor, Interferon alpha-beta | 1 | 2020 | 45 | 0.210 |
Why?
|
B7-H1 Antigen | 1 | 2020 | 45 | 0.200 |
Why?
|
Immunologic Factors | 1 | 2021 | 94 | 0.200 |
Why?
|
Bleomycin | 1 | 2020 | 16 | 0.200 |
Why?
|
Scleroderma, Localized | 1 | 2020 | 6 | 0.200 |
Why?
|
Genetic Testing | 1 | 2021 | 113 | 0.200 |
Why?
|
Vaccinia virus | 1 | 2020 | 99 | 0.200 |
Why?
|
Photography | 1 | 2019 | 33 | 0.190 |
Why?
|
Fibrosis | 1 | 2020 | 99 | 0.190 |
Why?
|
Cell Movement | 2 | 2019 | 393 | 0.190 |
Why?
|
Disease Susceptibility | 1 | 2020 | 144 | 0.190 |
Why?
|
Dermatologists | 1 | 2019 | 8 | 0.190 |
Why?
|
Ligands | 1 | 2020 | 396 | 0.190 |
Why?
|
Cell Death | 2 | 2018 | 241 | 0.190 |
Why?
|
Diagnostic Tests, Routine | 1 | 2019 | 40 | 0.190 |
Why?
|
Stem Cell Factor | 1 | 2018 | 24 | 0.180 |
Why?
|
Transcription Factors | 2 | 2004 | 1439 | 0.180 |
Why?
|
Receptors, Interleukin-15 | 1 | 2018 | 2 | 0.180 |
Why?
|
Heat-Shock Proteins | 1 | 2018 | 63 | 0.180 |
Why?
|
Aged | 4 | 2021 | 10797 | 0.180 |
Why?
|
Disease Management | 1 | 2020 | 181 | 0.180 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 596 | 0.180 |
Why?
|
Reactive Oxygen Species | 2 | 2016 | 188 | 0.180 |
Why?
|
Fas Ligand Protein | 1 | 2018 | 39 | 0.180 |
Why?
|
Pigmentation | 2 | 2015 | 21 | 0.180 |
Why?
|
Early Growth Response Protein 2 | 2 | 2010 | 8 | 0.180 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 137 | 0.180 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 476 | 0.180 |
Why?
|
Foundations | 1 | 2018 | 6 | 0.170 |
Why?
|
Pigmentation Disorders | 1 | 2018 | 5 | 0.170 |
Why?
|
Dendritic Cells | 1 | 2021 | 493 | 0.170 |
Why?
|
Global Health | 1 | 2019 | 136 | 0.170 |
Why?
|
Swine | 1 | 2018 | 298 | 0.170 |
Why?
|
Cell Proliferation | 3 | 2014 | 888 | 0.170 |
Why?
|
Toll-Like Receptor 7 | 1 | 2018 | 92 | 0.170 |
Why?
|
Phenylenediamines | 1 | 2017 | 4 | 0.170 |
Why?
|
Catechols | 1 | 2017 | 5 | 0.170 |
Why?
|
Hydroquinones | 1 | 2017 | 8 | 0.170 |
Why?
|
Pyrroles | 1 | 2017 | 49 | 0.170 |
Why?
|
Chemokine CXCL11 | 1 | 2017 | 4 | 0.170 |
Why?
|
Self Tolerance | 1 | 2017 | 16 | 0.160 |
Why?
|
Suction | 1 | 2017 | 24 | 0.160 |
Why?
|
Body Surface Area | 1 | 2017 | 14 | 0.160 |
Why?
|
Toll-Like Receptor 9 | 1 | 2018 | 194 | 0.160 |
Why?
|
Antigens, CD | 1 | 2018 | 307 | 0.160 |
Why?
|
Receptors, CXCR4 | 1 | 2016 | 34 | 0.160 |
Why?
|
Specimen Handling | 1 | 2016 | 40 | 0.160 |
Why?
|
Lymphocytes | 1 | 2017 | 178 | 0.160 |
Why?
|
Regeneration | 1 | 2017 | 92 | 0.160 |
Why?
|
Flow Cytometry | 1 | 2018 | 659 | 0.160 |
Why?
|
ROC Curve | 1 | 2017 | 226 | 0.150 |
Why?
|
Immune Complex Diseases | 1 | 2016 | 2 | 0.150 |
Why?
|
Chemokine CXCL2 | 1 | 2016 | 13 | 0.150 |
Why?
|
Gene-Environment Interaction | 1 | 2016 | 47 | 0.150 |
Why?
|
Dermatitis | 1 | 2016 | 19 | 0.150 |
Why?
|
Antigen-Antibody Complex | 1 | 2016 | 47 | 0.150 |
Why?
|
Child | 2 | 2019 | 3660 | 0.150 |
Why?
|
Bone Marrow Cells | 1 | 2016 | 219 | 0.150 |
Why?
|
Risk | 1 | 2016 | 364 | 0.150 |
Why?
|
Quality of Life | 2 | 2018 | 704 | 0.140 |
Why?
|
Antioxidants | 1 | 2017 | 205 | 0.140 |
Why?
|
Aged, 80 and over | 2 | 2021 | 4210 | 0.140 |
Why?
|
Insurance Coverage | 1 | 2015 | 94 | 0.140 |
Why?
|
Insurance, Health | 1 | 2015 | 112 | 0.140 |
Why?
|
International Classification of Diseases | 1 | 2015 | 127 | 0.140 |
Why?
|
Membrane Glycoproteins | 1 | 2018 | 648 | 0.140 |
Why?
|
Subcutaneous Fat | 1 | 2014 | 40 | 0.140 |
Why?
|
Prospective Studies | 1 | 2021 | 2469 | 0.130 |
Why?
|
DNA | 1 | 2018 | 700 | 0.130 |
Why?
|
Monocytes | 1 | 2016 | 335 | 0.130 |
Why?
|
Child, Preschool | 1 | 2019 | 1678 | 0.130 |
Why?
|
Immunity | 1 | 2014 | 89 | 0.130 |
Why?
|
Scalp | 1 | 2013 | 26 | 0.130 |
Why?
|
Wound Healing | 1 | 2014 | 152 | 0.130 |
Why?
|
High Mobility Group Proteins | 1 | 2013 | 20 | 0.130 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 33 | 0.130 |
Why?
|
Neutrophils | 1 | 2016 | 337 | 0.120 |
Why?
|
Risk Assessment | 1 | 2019 | 1572 | 0.120 |
Why?
|
Renal Circulation | 1 | 2021 | 11 | 0.110 |
Why?
|
Intestines | 1 | 2013 | 136 | 0.110 |
Why?
|
Adoptive Transfer | 1 | 2012 | 142 | 0.110 |
Why?
|
Methylation | 1 | 2021 | 121 | 0.110 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 68 | 0.110 |
Why?
|
Toxoplasmosis | 1 | 2010 | 12 | 0.100 |
Why?
|
Lymphocytic Choriomeningitis | 1 | 2010 | 76 | 0.100 |
Why?
|
RNA, Small Interfering | 3 | 2022 | 796 | 0.100 |
Why?
|
Combined Modality Therapy | 2 | 2022 | 300 | 0.090 |
Why?
|
DNA, Ribosomal Spacer | 1 | 2008 | 1 | 0.090 |
Why?
|
Itraconazole | 1 | 2008 | 7 | 0.090 |
Why?
|
DNA, Fungal | 1 | 2008 | 60 | 0.090 |
Why?
|
Culture Media | 1 | 2008 | 75 | 0.090 |
Why?
|
Interleukin-2 | 2 | 2009 | 158 | 0.090 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2009 | 142 | 0.090 |
Why?
|
Microbial Sensitivity Tests | 1 | 2008 | 156 | 0.090 |
Why?
|
Antifungal Agents | 1 | 2008 | 98 | 0.090 |
Why?
|
Sequence Analysis, DNA | 1 | 2008 | 374 | 0.080 |
Why?
|
Zinc Fingers | 2 | 2004 | 93 | 0.080 |
Why?
|
Molecular Sequence Data | 2 | 2008 | 1996 | 0.080 |
Why?
|
Reproducibility of Results | 2 | 2019 | 1315 | 0.070 |
Why?
|
Mice, Knockout | 3 | 2018 | 1893 | 0.070 |
Why?
|
Antigens, Ly | 2 | 2016 | 43 | 0.070 |
Why?
|
CD3 Complex | 1 | 2004 | 67 | 0.070 |
Why?
|
Clone Cells | 1 | 2004 | 106 | 0.070 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 69 | 0.070 |
Why?
|
Cell Line | 2 | 2009 | 1975 | 0.070 |
Why?
|
Up-Regulation | 1 | 2004 | 365 | 0.060 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2004 | 263 | 0.060 |
Why?
|
Mice, Inbred BALB C | 2 | 2018 | 849 | 0.060 |
Why?
|
Phosphorylation | 1 | 2004 | 823 | 0.060 |
Why?
|
Gene Silencing | 1 | 2004 | 357 | 0.060 |
Why?
|
Emollients | 1 | 2021 | 5 | 0.060 |
Why?
|
Lighting | 1 | 2019 | 14 | 0.050 |
Why?
|
Reference Standards | 1 | 2019 | 62 | 0.050 |
Why?
|
Cells, Cultured | 2 | 2016 | 2063 | 0.050 |
Why?
|
International Cooperation | 1 | 2019 | 83 | 0.050 |
Why?
|
Internationality | 1 | 2019 | 37 | 0.050 |
Why?
|
Ultraviolet Rays | 1 | 2019 | 129 | 0.050 |
Why?
|
Observer Variation | 1 | 2019 | 175 | 0.050 |
Why?
|
Immune System | 1 | 2020 | 124 | 0.040 |
Why?
|
Biopsy | 1 | 2020 | 329 | 0.040 |
Why?
|
RNA Interference | 1 | 2022 | 602 | 0.040 |
Why?
|
Ovalbumin | 1 | 2018 | 107 | 0.040 |
Why?
|
Janus Kinase 3 | 1 | 2017 | 3 | 0.040 |
Why?
|
Janus Kinase 1 | 1 | 2017 | 5 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2000 | 330 | 0.040 |
Why?
|
Autoantibodies | 1 | 2018 | 153 | 0.040 |
Why?
|
Th1 Cells | 1 | 2018 | 152 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 200 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 1534 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2017 | 75 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 383 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2017 | 75 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2016 | 1443 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 583 | 0.040 |
Why?
|
Cell Nucleus | 1 | 2000 | 578 | 0.040 |
Why?
|
Comorbidity | 1 | 2020 | 996 | 0.040 |
Why?
|
Endotoxins | 1 | 2016 | 70 | 0.040 |
Why?
|
Mast Cells | 1 | 2016 | 36 | 0.040 |
Why?
|
Neutrophil Infiltration | 1 | 2016 | 52 | 0.040 |
Why?
|
Regenerative Medicine | 1 | 2015 | 15 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2000 | 897 | 0.040 |
Why?
|
Inflammation Mediators | 1 | 2016 | 163 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 430 | 0.030 |
Why?
|
Nurses | 1 | 2015 | 75 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 121 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2000 | 809 | 0.030 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 1 | 2013 | 3 | 0.030 |
Why?
|
Lymphoid Enhancer-Binding Factor 1 | 1 | 2013 | 9 | 0.030 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 12 | 0.030 |
Why?
|
SOXC Transcription Factors | 1 | 2013 | 7 | 0.030 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2013 | 12 | 0.030 |
Why?
|
Circadian Rhythm | 1 | 2016 | 331 | 0.030 |
Why?
|
Interleukins | 1 | 2013 | 72 | 0.030 |
Why?
|
Lung | 1 | 2016 | 579 | 0.030 |
Why?
|
Rheology | 1 | 2013 | 55 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 68 | 0.030 |
Why?
|
Base Sequence | 2 | 2009 | 1318 | 0.030 |
Why?
|
Algorithms | 1 | 2017 | 884 | 0.030 |
Why?
|
Biomechanical Phenomena | 1 | 2013 | 222 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2013 | 211 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2013 | 135 | 0.030 |
Why?
|
Toxoplasma | 1 | 2010 | 25 | 0.030 |
Why?
|
Macrophages | 1 | 2016 | 916 | 0.020 |
Why?
|
Lymphocytic choriomeningitis virus | 1 | 2010 | 125 | 0.020 |
Why?
|
Columbidae | 1 | 2009 | 11 | 0.020 |
Why?
|
Cytochromes c | 1 | 2009 | 25 | 0.020 |
Why?
|
Transplantation Tolerance | 1 | 2009 | 63 | 0.020 |
Why?
|
Antigens | 1 | 2009 | 136 | 0.020 |
Why?
|
DNA Primers | 1 | 2009 | 296 | 0.020 |
Why?
|
Antigens, Surface | 1 | 2009 | 184 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2017 | 4410 | 0.020 |
Why?
|
Transfection | 1 | 2009 | 650 | 0.020 |
Why?
|
Risk Factors | 1 | 2015 | 4208 | 0.020 |
Why?
|
Promyelocytic Leukemia Protein | 1 | 2000 | 11 | 0.010 |
Why?
|
Snail Family Transcription Factors | 1 | 2000 | 25 | 0.010 |
Why?
|
Hydroxamic Acids | 1 | 2000 | 24 | 0.010 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2000 | 26 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2000 | 123 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2000 | 215 | 0.010 |
Why?
|
Histone Deacetylases | 1 | 2000 | 65 | 0.010 |
Why?
|
Conserved Sequence | 1 | 2000 | 177 | 0.010 |
Why?
|
RNA Splicing | 1 | 2000 | 169 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2000 | 195 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2000 | 324 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2000 | 267 | 0.010 |
Why?
|
Binding Sites | 1 | 2000 | 859 | 0.010 |
Why?
|
Chromatin | 1 | 2000 | 557 | 0.010 |
Why?
|